Proactive Investors - Run By Investors For Investors

Allergy Therapeutics hopes to launch "exciting" grass pollen allergy vaccine in 2019

Tim Higenbottam, R&D director at hay fever vaccine specialist Allergy Therapeutics (LON:AGY) tells Proactive Investors GrassMATAMPL is one of its two most advanced products in development.
He hopes the company will be in a position to start phase III studies at some point this year.
The company aims to launch the ground-breaking and "exciting" grass pollen allergy treatment in 2019 after all the trials are completed and the treatment is approved.

Meet Ariana Resources plc, Mandalay Resources Corp., Berkeley Energia Ltd, W Resources PLC and Horizonte Minerals Plc at our event, London, 08 December 2016. Register here »
View full AGY profile

Allergy Therapeutics plc Timeline

October 10 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.